Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session

3497 - PACTO: A single center, randomized, phase II study of the combination of nab-paclitaxel and gemcitabine with or without tocilizumab, an IL-6R inhibitor, as first-line treatment in patients with locally advanced or metastatic pancreatic cancer.

Date

09 Sep 2017

Session

Poster display session

Presenters

Inna Chen

Citation

Annals of Oncology (2017) 28 (suppl_5): v209-v268. 10.1093/annonc/mdx369

Authors

I. Chen1, J.S. Johansen2, T.A. Zimmers3, C. Dehlendorff4, V. Kirk Parner1, B. Vittrup Jensen1, D. Nielsen1

Author affiliations

  • 1 Oncology, Herlev and Gentofte Hospital, 2730 - Herlev/DK
  • 2 Medical Oncology, Herlev and Gentofte Hospital, 2730 - Herlev/DK
  • 3 Surgery, Indiana University School of Medicine, Indianapolis/US
  • 4 Statistics And Pharmacoepidemiology, Danish Cancer Society Research Center, Danish Cancer Society, 2100 - Copenhagen/DK
More

Resources

Abstract 3497

Background

High plasma levels of interleukin-6 (IL-6) are found in patients with pancreatic cancer (PC) and in part facilitate systemic inflammation cascade and cachexia. The current phase 2 trial (PACTO) will evaluate the efficacy and safety of nab-paclitaxel and gemcitabine with or without tocilizumab, an IL-6R inhibitor, as first-line treatment in patients with advanced PC.

Trial design

Eligible patients with chemotherapy-naïve locally advanced or metastatic PC (n = 140), ECOG performance status (PS) of 0–1, and presence of a systemic inflammatory response (elevated C-reactive protein [CRP] levels or a modified Glasgow Prognostic Score [mGPS] of 1 or 2) will be randomized 1:1 (stratified by PS [PS 0 vs PS 1] and stage [locally advanced vs metastatic disease]) to receive tocilizumab 8 mg/kg on day 1 in combination with nab-paclitaxel 125 mg/m2 plus gemcitabine 1000 mg/m2 or nab-paclitaxel 125 mg/m2 plus gemcitabine 1000 mg/m2 on days 1, 8, and 15 of a 28-day cycle. Before randomization begins, the first six patients enrolled will be treated in the investigational arm for safety assessment and will not be included in the final analysis. The primary endpoint is overall survival (OS) rate at 6 months. Assuming a 6 month OS rate of 67% in the reference arm and an improvement by at least 20% by the intervention (corresponding to a 6 month OS of 80%), a total of 140 patients are needed (1:1 allocation) to obtain a statistical power of 80% with a significance level of 5%. Secondary endpoints include change from baseline PS, assessed by both investigator and patient, progression-free survival, OS, tumor response per RECIST 1.1, safety and assessment of quality of life by EORTC QLQ-C30. Patients will be assessed by CT scan every 8 weeks. Exploratory endpoints include circulating tumor DNA KRAS, body composition changes, plasma biomarkers of cachexia and inflammation. Treatment will continue as long as it is tolerated until disease progression. Enrollment was initiated in January 2017 and is ongoing.

Clinical trial identification

NCT02866383

Legal entity responsible for the study

Herlev & Gentofte Hospital

Funding

Celgene

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.